Pilbara Minerals Limited

PLS

Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 768 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australia’s resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum (tpa) lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.

Lake Resources N.L.

LKE

Lake Resources NL, is a lithium exploration company, which is focused on exploring lithium basins and pegmatites in Argentina. The company is headquartered in Sydney, New South Wales. The company went IPO on 2001-08-29. The firm also has three additional early-stage projects in this region, including Olaroz, Cauchari and Pasode Jama. The flagship Kachi Project is located in Argentina’s Catamarca Province at the southern end of the Lithium Triangle. The project comprises 705 square kilometers (Km2) of leases and lease applications over a brine-bearing basin 20 kilometers (km) long, 15 km wide and 400-800 meter deep centered. The Cauchari Lithium Brine Project in Jujuy Province. The Paso de Jama Lithium Brine Project in Jujuy Province is comprised of over 59,000 hectares. The Olaroz Lithium Brine Project covers 45,000 hectares.

Core Lithium Ltd

CXO

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-02-11. The company owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Napperby Uranium, Yerelina and Mt Freeling, and Blueys-Inkheart. The Shoobridge Lithium Project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. The Anningie and Barrow Creek encompass eight exploration licenses over approximately 2,000 km2 in and around the Anningie and Barrow Creek tin-tantalum pegmatite fields in the Northern Territory. Napperby is an advanced uranium project within the central Northern Territory.

Neuren Pharmaceuticals Limited

NEU

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Liontown Resources Limited

LTR

Liontown Resources Ltd. engages in the exploration and evaluation of minerals. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-27. The firm controls two major hard rock lithium deposits. The firm's projects include Kathleen Valley Project and Buldania Project. The Kathleen Valley Project is located in an established mining region about 60 kilometers north of Leinster and 680 kilometers north-east of Perth, Western Australia. The Kathleen Valley Lithium Project is a Tier-1 battery metals asset with excellent grade and scale in one of world's best mining districts. The Buldania Project is in the Eastern Goldfields Province of Western Australia, approximately 600 kilometers east of Perth. The Project is close to major road and rail infrastructure with direct access to the Port of Esperance 200 kilometers to the south. The firm's downstream expansion project includes investigating the potential for an integrated refinery to upgrade its spodumene from the Kathleen Valley mine to higher value lithium products.